Market closed
89bio, Inc/$ETNB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About 89bio, Inc
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Ticker
$ETNB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
70
Website
89bio, Inc Metrics
BasicAdvanced
$1.1B
Market cap
-
P/E ratio
-$1.98
EPS
1.00
Beta
-
Dividend rate
Price and volume
Market cap
$1.1B
Beta
1
52-week high
$16.63
52-week low
$6.88
Average daily volume
644K
Financial strength
Current ratio
13.921
Quick ratio
13.223
Long term debt to equity
4.237
Total debt to equity
5.311
Interest coverage (TTM)
-53.70%
Management effectiveness
Return on assets (TTM)
-22.25%
Return on equity (TTM)
-36.50%
Valuation
Price to book
2.03
Price to tangible book (TTM)
2.03
Price to free cash flow (TTM)
-5.309
Growth
Earnings per share change (TTM)
-5.78%
3-year earnings per share growth (CAGR)
-15.37%
What the Analysts think about 89bio, Inc
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for 89bio, Inc stock.
89bio, Inc Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
89bio, Inc Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
89bio, Inc News
AllArticlesVideos
89bio to Participate in the UBS Global Healthcare Conference
GlobeNewsWire·3 days ago
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
GlobeNewsWire·3 weeks ago
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for 89bio, Inc stock?
89bio, Inc (ETNB) has a market cap of $1.1B as of November 08, 2024.
What is the P/E ratio for 89bio, Inc stock?
The price to earnings (P/E) ratio for 89bio, Inc (ETNB) stock is 0 as of November 08, 2024.
Does 89bio, Inc stock pay dividends?
No, 89bio, Inc (ETNB) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next 89bio, Inc dividend payment date?
89bio, Inc (ETNB) stock does not pay dividends to its shareholders.
What is the beta indicator for 89bio, Inc?
89bio, Inc (ETNB) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.